Executive Summary
This intelligence stream covers four US-listed companies that received trading suspension or delisting notices from Nasdaq and NYSE American between May 19 and May 29, 2026. All four filings carry negative sentiment, with materiality scores ranging from 8 to 9 out of 10, indicating high risk of trading disruption.
The primary causes are regulatory non-compliance: two companies (NusaTrip and Gencor Industries) failed to file periodic reports on time, while HCW Biologics and iSpecimen face minimum bid price and stockholders' equity deficiencies, respectively. No period-over-period financial trends or insider trading activity were disclosed in these filings, as they focus solely on regulatory notices. The filings reveal a common pattern of companies relying on compliance plans and appeal processes to avoid immediate delisting, with deadlines ranging from 45 to 180 days. The most critical development is HCW Biologics' strict extension conditions, including immediate delisting if the bid price deficiency recurs before September 22, 2026. Market implications are significant: investors face potential liquidity events and price volatility as these companies navigate regulatory hurdles. No forward-looking guidance, capital allocation changes, or transaction details were reported, underscoring the reactive nature of these filings.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 8-K
Tracking the trend? Catch up on the prior US SEC Trading Suspension Halt Orders digest from May 29, 2026.
Investment Signals (8)
- NusaTrip ↓ (BEARISH)▲
Received Nasdaq delinquency notice for late 10-K and 10-Q filings; expects to file within 60 days; no immediate delisting, but failure to regain compliance could lead to delisting by October 12, 2026
- HCW Biologics ↓ (BEARISH)▲
Granted Nasdaq extension until July 29, 2026, to meet $1 bid price; already used a 1-for-40 reverse split; immediate delisting if deficiency recurs before September 22, 2026
- iSpecimen ↓ (BEARISH)▲
Received delisting notice for stockholders' equity of only $814,038 vs. $2.5M requirement; 45 days to submit compliance plan; stock continues trading but with high delisting risk
- Gencor Industries ↓ (BEARISH)▲
NYSE American delinquency notice for late Q2 FY2026 10-Q; six-month cure period from May 18, 2026; potential delisting if not filed; no immediate trading halt
- All Companies▲
No insider trading activity reported in any filing, suggesting management is not signaling confidence through purchases during these crises [NEUTRAL/BEARISH]
- All Companies (NEUTRAL)▲
No forward-looking guidance or revenue/margin trends disclosed, limiting ability to assess fundamental recovery prospects
- All Companies (BEARISH)▲
No capital allocation actions (dividends, buybacks) reported, indicating financial strain or regulatory focus
- HCW Biologics ↓ (BEARISH)▲
Strict compliance conditions with immediate delisting trigger if bid price falls below $1 again before September 22, 2026; high probability of failure given past reverse split
Risk Flags (8)
- NusaTrip/Delisting Risk↓ [HIGH RISK]▼
Failure to file 10-K and 10-Q by July 27, 2026, could lead to Nasdaq delisting; company is an emerging growth company with limited resources
- HCW Biologics/Immediate Delisting↓ [HIGH RISK]▼
If bid price drops below $1 for 20 consecutive trading days before July 29, 2026, or if deficiency recurs before September 22, 2026, immediate delisting without cure
- iSpecimen/Equity Deficiency↓ [HIGH RISK]▼
Stockholders' equity of $814,038 is 67% below the $2.5M requirement; also fails alternative listing standards; 45-day compliance plan submission deadline
- Gencor Industries/Filing Delay↓ [HIGH RISK]▼
Q2 FY2026 10-Q due May 18, 2026, not filed; six-month cure period but NYSE may not grant extension; potential delisting
- HCW Biologics/Reverse Split History↓ [HIGH RISK]▼
Already used 1-for-40 reverse split on April 11, 2025, making it ineligible for standard 180-day cure; indicates severe price deterioration
- All Companies/No Insider Activity [MODERATE RISK]▼
Absence of insider buying during distress signals lack of management confidence or inability to purchase shares
- All Companies/No Financial Guidance [MODERATE RISK]▼
No revenue, margin, or earnings data in filings, creating information vacuum for investors assessing recovery
- iSpecimen/Appeal Uncertainty↓ [MODERATE RISK]▼
If compliance plan rejected, company must appeal to Nasdaq Hearings Panel; no guarantee of success
Opportunities (7)
- NusaTrip/Catalyst↓ (OPPORTUNITY)◆
If company files delinquent reports within 60 days (by July 27, 2026), delisting risk could be removed, potentially triggering a relief rally
- HCW Biologics/Deadline Play↓ (OPPORTUNITY)◆
If stock maintains $1 bid price through July 29, 2026, extension conditions are met; short-term traders could profit from volatility around compliance dates
- iSpecimen/Turnaround↓ (OPPORTUNITY)◆
If company raises equity or restructures to meet $2.5M requirement within 45 days, delisting notice could be withdrawn; potential for significant upside if successful
- Gencor Industries/Cure Period↓ (OPPORTUNITY)◆
Six-month window to file 10-Q; if filed promptly, stock may recover as regulatory uncertainty clears
- All Companies/Short Squeeze Potential (OPPORTUNITY)◆
High delisting risk may attract short sellers; positive compliance news could trigger short squeezes in low-float stocks
- NusaTrip/Compliance Plan↓ (OPPORTUNITY)◆
If Nasdaq accepts plan by July 27, 2026, company gets until October 12, 2026, to file; extended timeline reduces immediate pressure
- HCW Biologics/Strict Conditions↓ (OPPORTUNITY)◆
Some investors may view the strict conditions as a floor, expecting management to take extraordinary measures to maintain listing
Sector Themes (6)
- Regulatory Non-Compliance Cluster◆
Four companies received trading suspension/delisting notices within 10 days (May 19-29, 2026), indicating a potential increase in exchange enforcement actions against small-cap issuers
- Late Filing Epidemic◆
Two of four companies (NusaTrip and Gencor Industries) failed to file periodic reports on time, suggesting systemic issues with financial reporting among micro-cap companies
- Financial Health Deterioration◆
iSpecimen's stockholders' equity of $814,038 vs. $2.5M requirement highlights capital erosion in small biotech/tech firms; HCW Biologics' reverse split signals similar distress
- No Insider Confidence Signals◆
Across all four filings, no insider trading activity was reported, indicating management is not using personal capital to signal confidence during crises
- Reliance on Compliance Plans◆
All companies are pursuing compliance plans or appeals rather than immediate fixes, suggesting limited financial flexibility to address deficiencies quickly
- Sector Concentration Risk◆
Three of four companies (NusaTrip, HCW Biologics, iSpecimen) are in healthcare/tech sectors, which are prone to cash burn and regulatory scrutiny
Watch List (8)
-
Watch for submission by July 27, 2026; acceptance could extend deadline to October 12, 2026; failure triggers delisting risk
-
Monitor daily stock price through July 29, 2026; any close below $1 for 20 consecutive days triggers immediate delisting
-
45-day submission window ends around July 13, 2026; watch for equity raise or restructuring announcement
-
Six-month cure period ends November 18, 2026; earlier filing would reduce delisting risk; watch for NYSE extension decision
-
Even if compliant by July 29, 2026, any bid price deficiency before September 22, 2026, causes immediate delisting; extended monitoring needed
- All Companies/Exchange Announcements👁
Watch for Nasdaq and NYSE American decisions on compliance plans, extensions, or delisting notices
-
Monitor quarterly filings for equity changes; any improvement toward $2.5M would be positive catalyst
-
Actual filing of delinquent reports will be key catalyst; watch for any material adverse changes in financials
Filing Analyses
(4)
01-06-2026
NusaTrip Inc. received a Nasdaq delinquency notice on May 27, 2026 for failing to timely file its Form 10-K for FY2025 and Form 10-Q for Q1 2026, violating Listing Rule 5250(c)(1). The company has 60 days (until July 27, 2026) to submit a compliance plan; if accepted, it may have until October 12, 2026 to regain compliance. While the notice has no immediate delisting effect, failure to regain compliance could result in delisting, and the company expects to file the delinquent reports within the 60-day period.
- · The company is an emerging growth company as defined under SEC rules.
- · The delinquent filings are the Annual Report on Form 10-K for the period ended December 31, 2025 and the Quarterly Report on Form 10-Q for the period ended March 31, 2026.
- · If Nasdaq does not accept the compliance plan, the company may appeal to a Nasdaq Hearings Panel.
- · A press release regarding the notice was issued on June 1, 2026, as required by Nasdaq Listing Rule 5810(b).
01-06-2026
HCW Biologics Inc. received an extension from the Nasdaq Hearings Panel until July 29, 2026, to regain compliance with the minimum bid price of $1 per share for continued listing on The Nasdaq Capital Market. The company had previously failed the Bid Price Rule and, due to a 1-for-40 reverse stock split on April 11, 2025, was not eligible for the standard 180-day cure period. The extension is subject to strict conditions, including demonstrating a bid price of at least $1 for 20 consecutive trading days by the deadline, with immediate delisting if the deficiency recurs before September 22, 2026.
- · The company was not afforded a 180-calendar day cure period because it had already effected a 1-for-40 reverse stock split on April 11, 2025.
- · If the company becomes deficient with the Bid Price Rule again before September 22, 2026, it will be immediately delisted.
- · If the company becomes non-compliant with any other listing rule before September 22, 2026, it has seven calendar days to propose a cure plan.
- · Upon regaining compliance, the Panel intends to impose a Discretionary Panel Monitor for an additional one-year period.
01-06-2026
iSpecimen Inc. (ISPC) received a delisting notice from Nasdaq on May 29, 2026, for failing to meet the minimum $2,500,000 stockholders' equity requirement under Listing Rule 5550(b)(1). As of March 31, 2026, the company reported stockholders' equity of only $814,038, and Nasdaq noted it also fails alternative listing standards. The company has 45 days to submit a compliance plan and may receive up to 180 days to regain compliance, but there is no assurance of acceptance or ultimate compliance.
- · The company's common stock continues to trade on Nasdaq Capital Market under symbol 'ISPC' with no immediate effect on listing or trading.
- · If Nasdaq rejects the compliance plan, iSpecimen has the opportunity to appeal to a Nasdaq Hearings Panel.
01-06-2026
Gencor Industries received a delinquency notification from NYSE American on May 19, 2026, for failing to timely file its Q2 FY2026 Form 10-Q. The company has a six-month cure period to file the delinquent report, but faces potential delisting if it fails to comply. The filing indicates a negative regulatory event with material uncertainty.
- · The delinquency notification was received on May 19, 2026, for the Form 10-Q due May 18, 2026.
- · The company has an initial six-month period from May 18, 2026, to regain compliance.
- · NYSE may grant an additional six-month extension at its discretion.
- · The company expects to file within the six-month period but cannot assure timely filing.
- · NYSE may commence suspension and delisting proceedings at any time if circumstances warrant.
Get daily alerts with 8 investment signals, 8 risk alerts, 7 opportunities and full AI analysis of all 4 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US SEC Trading Suspension Halt Orders
🇺🇸 More from United States
View all →June 01, 2026
US Pre-Market SEC Filings Roundup — June 01, 2026
US Pre-Market SEC Filings Roundup
June 01, 2026
US Corporate Distress Financial Stress SEC Filings — June 01, 2026
US Corporate Distress Financial Stress SEC Filings
June 01, 2026
US Merger & Acquisition SEC Filings — June 01, 2026
US Merger & Acquisition SEC Filings
June 01, 2026
US Corporate Board Director Changes SEC Filings — June 01, 2026
US Corporate Board Director Changes SEC Filings